Patiromer-Facilitated Renin-Angiotensin-Aldosterone System Inhibitor Utilization in Patients with Heart Failure with or without Comorbid Chronic Kidney Disease: Subgroup Analysis of DIAMOND Randomized Trial
Patiromer enabled use of RAASi, controlled sK+, and minimized HK risk in patients with HFrEF, with greater effect sizes for most endpoints noted in patient subgroups with lower eGFR. Patiromer was well tolerated by patients in all eGFR subgroups.
Authors
- José Carlos Nicolau (ORCID: https://orcid.org/0000-0002-9680-3689)
- Justin Adrian Ezekowitz (ORCID: https://orcid.org/0000-0002-2724-4086)
- Alexander Parkhomenko (ORCID: https://orcid.org/0000-0002-3563-9627)
- Antoni Bayés‐Genís (ORCID: https://orcid.org/0000-0002-3044-197X)
- Piotr Ponikowski (ORCID: https://orcid.org/0000-0002-3391-7064)
- Patrick Rossignol (ORCID: https://orcid.org/0000-0001-8009-3873)
- Bertram Pitt (ORCID: https://orcid.org/0000-0001-5880-275X)
- Andrew J.S. Coats (ORCID: https://orcid.org/0000-0002-2771-4260)
- Eliodoro Castro-Montes
- Marco Metra (ORCID: https://orcid.org/0000-0001-6691-8568)
- Robert John Mentz (ORCID: https://orcid.org/0000-0002-3222-1719)
- Sandra Waechter (ORCID: https://orcid.org/0009-0007-3338-6607)
- Petar Seferović (ORCID: https://orcid.org/0000-0002-1955-4199)
- Alain Cohen‐Solal (ORCID: https://orcid.org/0000-0003-1055-2231)
- Javed Butler (ORCID: https://orcid.org/0000-0003-4267-6933)
- Amandine Perrin
- Stefan D. Anker (ORCID: https://orcid.org/0000-0003-3331-7314)
- Lars H. Lund
- Mikhail Kosiborod
- Michael Boehm
- Jeffrey Budden
- Michele Senni
Institutions
- University of Maryland, Baltimore (US)
- Karolinska University Hospital (SE)
- Serbian Academy of Sciences and Arts (RS)
- Saint Luke's Health System (US)
- University of Alberta (CA)
- Inserm (FR)
- Autonomous University of Queretaro (MX)
- Duke University (US)
- National and Kapodistrian University of Athens (GR)
- University of Michigan (US)
- Princess Grace Hospital Centre (MC)
- The Heart Research Institute (AU)
- Karolinska Institutet (SE)
- Wroclaw Medical University (PL)
- Universitätsklinikum des Saarlandes (DE)
- Centro de Investigación en Red en Enfermedades Cardiovasculares (ES)
- Assistance Publique – Hôpitaux de Paris (FR)
- Vifor Pharma (Switzerland) (CH)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- Ospedale Papa Giovanni XXIII (IT)
- Hôpital Lariboisière (FR)
- German Centre for Cardiovascular Research (DE)
- Saint Luke's Hospital (US)
- University of Arts in Belgrade (RS)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- University General Hospital Attikon (GR)
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (BR)
- Institute of Genetic and Regenerative Medicine of the National Academy of Medical Sciences of Ukraine (UA)
- Hospital Universitari Germans Trias i Pujol (ES)
- French Clinical Research Infrastructure Network (FR)
- Université de Lorraine (FR)
- Saarland University (DE)
Publication Details
- Journal
- American Journal of Nephrology
- Published
- 2024-08-19
- DOI
- https://doi.org/10.1159/000540453
- Citations
- 4
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.61
Funders
- Vifor Pharma